Cargando…
Regulatory Aspects in Using Surrogate Markers in Clinical Trials
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
2005
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7123225/ http://dx.doi.org/10.1007/0-387-27080-9_3 |
| _version_ | 1783515590092128256 |
|---|---|
| author | Chakravarty, Aloka |
| author_facet | Chakravarty, Aloka |
| author_sort | Chakravarty, Aloka |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7123225 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2005 |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-71232252020-04-06 Regulatory Aspects in Using Surrogate Markers in Clinical Trials Chakravarty, Aloka The Evaluation of Surrogate Endpoints Article 2005 /pmc/articles/PMC7123225/ http://dx.doi.org/10.1007/0-387-27080-9_3 Text en © Springer Science+Business Media, Inc. 2005 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
| spellingShingle | Article Chakravarty, Aloka Regulatory Aspects in Using Surrogate Markers in Clinical Trials |
| title | Regulatory Aspects in Using Surrogate Markers in Clinical Trials |
| title_full | Regulatory Aspects in Using Surrogate Markers in Clinical Trials |
| title_fullStr | Regulatory Aspects in Using Surrogate Markers in Clinical Trials |
| title_full_unstemmed | Regulatory Aspects in Using Surrogate Markers in Clinical Trials |
| title_short | Regulatory Aspects in Using Surrogate Markers in Clinical Trials |
| title_sort | regulatory aspects in using surrogate markers in clinical trials |
| topic | Article |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7123225/ http://dx.doi.org/10.1007/0-387-27080-9_3 |
| work_keys_str_mv | AT chakravartyaloka regulatoryaspectsinusingsurrogatemarkersinclinicaltrials |